Biochem Pharma (BCHE) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biochem Pharma (BCHE)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: JDN who wrote (583)	2/3/1999 12:30:00 AM
From: Richard Haugland	Read Replies (2) of 783

I would hope that the reason for BCHE to not pass 30 is the general tenure of the market, not a building resistance of the virus to treatment. This message is that there is a much larger market yet even in the US for such treatments biz.yahoo.com I am still very optimistic on BCHE, especially in late 1999 when it starts to derive revenues/royalties from sales of lamivudine. Also, it sounded like BCHE would soon announce sale of their diagnostics business, which may have been a drag on earnings/costs. Currently there are only 3 analysts who have made projections for next Q (18 US cents in Zacks). biz.yahoo.com I expect that the number of analysts making projections will increase in the next two weeks (ther are 14 numbers for annual projections) and we will see a number closer to last quarter's 23 cents soon for the next Q. I don't see any real reason for a reduction in revenues/royalties during this next Q and, IMO, we should see some further increase from sales for hepatitis B.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next